Synonym |
Thai / English name |
Part Used : น้ำมันActivity : DRUG INTERACTIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 8% dietary flaxseed oilDuration : 4 weeks?Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : TrastuzumabDose/Conc.(drug) : 2.5 mg/kg, twice daily, ip.Result : -Remark : Control tumors significantly grew 187%, TRAS2.5 treated tumors did not change, while TRAS5, FO + TRAS2.5 and FO + TRAS5 treated tumors significantly regressed 75%, 89% and 84%, respectively, after 4 weeks treatment. Two weeks after stopping TRAS treatment while continuing on same diet, tumor size in FO + TRAS2.5 group was 87% lower than in TRAS2.5 group and was not different from TRAS5 group with or without FO. Combined TRAS2.5 treatment with FO caused a significantly lower tumor cell proliferation and higher apoptosis compared to TRAS2.5 treatment alone and showed similar effects to TRAS5 treatment with or without FO.Note : Type of experiment: Ovariectomized athymic mice were separated into five treatment groups such that tumor size and body weight were similar among treatment groups: Control group was fed the basal diet (BD); TRAS2.5 group and TRAS5 group received 2.5 and 5.0 mg/kg body weight Trastuzumab (TRAS) intraperitoneal injections twice weekly after loading doses of 5 and 10 mg/kg, respectively, and fed the BD; FO + TRAS2.5 group and FO + TRAS5 group received, respectively, the same treatment as TRAS2.5 group and TRAS5 group but fed the flaxseed oil (FO), diet.
Part Used : น้ำมันActivity : APOPTOSIS INDUCTIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 8% dietary flaxseed oilDuration : 4 weeks?Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : TrastuzumabDose/Conc.(drug) : 2.5 mg/kg, twice daily, ip.Result : -Remark : Control tumors significantly grew 187%, TRAS2.5 treated tumors did not change, while TRAS5, FO + TRAS2.5 and FO + TRAS5 treated tumors significantly regressed 75%, 89% and 84%, respectively, after 4 weeks treatment. Two weeks after stopping TRAS treatment while continuing on same diet, tumor size in FO + TRAS2.5 group was 87% lower than in TRAS2.5 group and was not different from TRAS5 group with or without FO. Combined TRAS2.5 treatment with FO caused a significantly lower tumor cell proliferation and higher apoptosis compared to TRAS2.5 treatment alone and showed similar effects to TRAS5 treatment with or without FO.Note : Type of experiment: Ovariectomized athymic mice were separated into five treatment groups such that tumor size and body weight were similar among treatment groups: Control group was fed the basal diet (BD); TRAS2.5 group and TRAS5 group received 2.5 and 5.0 mg/kg body weight Trastuzumab (TRAS) intraperitoneal injections twice weekly after loading doses of 5 and 10 mg/kg, respectively, and fed the BD; FO + TRAS2.5 group and FO + TRAS5 group received, respectively, the same treatment as TRAS2.5 group and TRAS5 group but fed the flaxseed oil (FO), diet.
Part Used : น้ำมันActivity : ANTITUMOR ACTIVITYSolvent/Active Compound : -Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 8% dietary flaxseed oilDuration : 4 weeks?Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : TrastuzumabDose/Conc.(drug) : 2.5 mg/kg, twice daily, ip.Result : -Remark : Control tumors significantly grew 187%, TRAS2.5 treated tumors did not change, while TRAS5, FO + TRAS2.5 and FO + TRAS5 treated tumors significantly regressed 75%, 89% and 84%, respectively, after 4 weeks treatment. Two weeks after stopping TRAS treatment while continuing on same diet, tumor size in FO + TRAS2.5 group was 87% lower than in TRAS2.5 group and was not different from TRAS5 group with or without FO. Combined TRAS2.5 treatment with FO caused a significantly lower tumor cell proliferation and higher apoptosis compared to TRAS2.5 treatment alone and showed similar effects to TRAS5 treatment with or without FO.Note : Type of experiment: Ovariectomized athymic mice were separated into five treatment groups such that tumor size and body weight were similar among treatment groups: Control group was fed the basal diet (BD); TRAS2.5 group and TRAS5 group received 2.5 and 5.0 mg/kg body weight Trastuzumab (TRAS) intraperitoneal injections twice weekly after loading doses of 5 and 10 mg/kg, respectively, and fed the BD; FO + TRAS2.5 group and FO + TRAS5 group received, respectively, the same treatment as TRAS2.5 group and TRAS5 group but fed the flaxseed oil (FO), diet.
Part Used : น้ำมันActivity : CELL PROLIFERATION INHIBITIONSolvent/Active Compound : -Type of experiment : in vivoType of animal : mouseType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : 8% dietary flaxseed oilDuration : 4 weeks?Type of interaction : P.Kinetics & P.DynamicsInteraction with drug : TrastuzumabDose/Conc.(drug) : 2.5 mg/kg, twice daily, ip.Result : -Remark : Control tumors significantly grew 187%, TRAS2.5 treated tumors did not change, while TRAS5, FO + TRAS2.5 and FO + TRAS5 treated tumors significantly regressed 75%, 89% and 84%, respectively, after 4 weeks treatment. Two weeks after stopping TRAS treatment while continuing on same diet, tumor size in FO + TRAS2.5 group was 87% lower than in TRAS2.5 group and was not different from TRAS5 group with or without FO. Combined TRAS2.5 treatment with FO caused a significantly lower tumor cell proliferation and higher apoptosis compared to TRAS2.5 treatment alone and showed similar effects to TRAS5 treatment with or without FO.Note : Type of experiment: Ovariectomized athymic mice were separated into five treatment groups such that tumor size and body weight were similar among treatment groups: Control group was fed the basal diet (BD); TRAS2.5 group and TRAS5 group received 2.5 and 5.0 mg/kg body weight Trastuzumab (TRAS) intraperitoneal injections twice weekly after loading doses of 5 and 10 mg/kg, respectively, and fed the BD; FO + TRAS2.5 group and FO + TRAS5 group received, respectively, the same treatment as TRAS2.5 group and TRAS5 group but fed the flaxseed oil (FO), diet.